Sexual Health

Kate McLean, MD, describes how newly defined bacterial vaginosis subtypes could validate patient symptoms and inform treatment.

Alcohol use increased from 8% to 44% postpartum among pregnant people with HIV, with distinct risk factors identified for alcohol vs cannabis use.

A randomized controlled trial among sexually active premenopausal women found that anterior wall PRP injections vs control led to greater improvement in sexual function.

Researchers reported in JAMA Health Forum that while expanded prenatal syphilis mandates improve near-term detection, they require additional public health support to maintain long-term efficacy.

Data suggest that thermal biomodulation via radiofrequency improves vaginal lubrication and reduces pain during intercourse for postmenopausal women.

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 lb.

Phase 3 results show oral zoliflodacin was non-inferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

DARE to PLAY sildenafil cream is now available for prescribing in select states as a non-hormonal topical option to improve genital blood flow and arousal.

A US study of women over 60 found that frequent sex toy use during masturbation was strongly associated with higher orgasm frequency.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in a Q&A.

Experts discuss the future of healthcare, emphasizing innovative STI care, education, and the importance of collaboration in improving patient outcomes.

Panelists explore the future of STI screening and management, emphasizing the importance of guidelines and innovative diagnostics in women's health.

Discover how accessible STI testing and early detection enhance maternal-fetal health, reducing risks for mothers and newborns alike.

Innovations in diagnostic testing enhance patient care, empowering women with at-home options and faster access to essential health services.

Experts discuss the FDA's priority review of gepotidacin, an oral gonorrhea treatment, highlighting its potential to improve women's health and access to care.

Experts discuss updates in STI testing, congenital conditions, and best practices for pregnant women in this insightful healthcare panel.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

Study finds women 65+ experience sexual dysfunction at rates similar to midlife women but report less distress over sexual health concerns.

FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients 12 years and older.

The FDA has granted priority review to expand flibanserin (Addyi; Sprout Pharmaceuticals) use to postmenopausal women, potentially broadening access to treatment for hypoactive sexual desire disorder.

The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.